Kling doses first subject in Phase Ib solid tumour antibody trial

Kling doses first subject in Phase Ib solid tumour antibody trial

Submitted by admin on September 30, 2022 - 11:02am
Source: 
Clinical Trials Arena
News Tags: 
Kling Biotherapeutics
KBA1412-101
solid tumors
clinical trials
Headline: 
Kling doses first subject in Phase Ib solid tumour antibody trial
snippet: 

Kling Biotherapeutics has dosed the first subject in its Phase Ib KBA1412-101 clinical trial of antibody KBA1412 in adults with advanced solid tumours unresponsive to standard of care.

Do Not Allow Advertisers to Use My Personal information